Evolus, Inc. (EOLS) stock
EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$7.07+0.38 (+5.68%)
Close on Nov 18, 2026Market cap $466.98MP/E –Yield –
Evolus operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Evolus's operating cash flow for the twelve months ending Jun 30, 2026 was -$15.38M. For fiscal 2025 it was -$42.27M. The highest annual figure on record is -$13.22M in fiscal 2017.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$42.27M | – |
| FY2024 | Dec 31, 2024 | -$18.00M | – |
| FY2023 | Dec 31, 2023 | -$34.01M | – |
| FY2022 | Dec 31, 2022 | -$84.91M | – |
| FY2021 | Dec 31, 2021 | -$33.39M | – |
| FY2020 | Dec 31, 2020 | -$57.87M | – |
| FY2019 | Dec 31, 2019 | -$93.38M | – |
| FY2018 | Dec 31, 2018 | -$25.67M | – |
| FY2017 | Dec 31, 2017 | -$13.22M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$3.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.95M | – |
| Q4 FY2025 | Dec 31, 2025 | $12.83M | +166.8% |
| Q3 FY2025 | Sep 30, 2025 | -$14.67M | – |
| Q2 FY2025 | Jun 30, 2025 | -$24.79M | – |
| Q1 FY2025 | Mar 31, 2025 | -$15.63M | – |
| Q4 FY2024 | Dec 31, 2024 | $4.81M | +491.4% |
| Q3 FY2024 | Sep 30, 2024 | -$5.72M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.47M | – |
| Q1 FY2024 | Mar 31, 2024 | -$10.62M | – |
| Q4 FY2023 | Dec 31, 2023 | $813.00K | – |
| Q3 FY2023 | Sep 30, 2023 | -$924.00K | – |
| Q2 FY2023 | Jun 30, 2023 | -$13.31M | – |
| Q1 FY2023 | Mar 31, 2023 | -$20.59M | – |
| Q4 FY2022 | Dec 31, 2022 | -$8.77M | – |
| Q3 FY2022 | Sep 30, 2022 | -$17.05M | – |
| Q2 FY2022 | Jun 30, 2022 | -$20.89M | -229.6% |
| Q1 FY2022 | Mar 31, 2022 | -$38.20M | – |
| Q4 FY2021 | Dec 31, 2021 | -$9.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$32.13M | – |
| Q2 FY2021 | Jun 30, 2021 | $16.12M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.34M | – |
| Q4 FY2020 | Dec 31, 2020 | -$2.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$13.71M | – |
| Q2 FY2020 | Jun 30, 2020 | -$13.95M | – |
| Q1 FY2020 | Mar 31, 2020 | -$27.95M | – |
| Q4 FY2019 | Dec 31, 2019 | -$15.92M | – |
| Q3 FY2019 | Sep 30, 2019 | -$25.10M | – |
| Q2 FY2019 | Jun 30, 2019 | -$33.16M | – |
| Q1 FY2019 | Mar 31, 2019 | -$19.20M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.01M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.80M | – |
| Q2 FY2018 | Jun 30, 2018 | -$5.66M | – |
| Q1 FY2018 | Mar 31, 2018 | -$2.20M | – |
| Q4 FY2017 | Dec 31, 2017 | -$1.00M | – |
| Q3 FY2017 | Sep 30, 2017 | -$3.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$3.21M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.58M | – |
See a number that looks wrong?